Imam Hussain Holy Shrine signs contracts with international companies to transfer biopharmaceutical manufacturing technologies to Iraq
The Health and Medical Education Authority of the Holy Shrine of Imam Hussain announced the signing of contracts with a group of reputable international companies to transfer biopharmaceutical manufacturing technologies to Iraq, as part of preparations to establish an advanced city specializing in the production of modern medicines within the country.
In a statement obtained by the official website, the authority confirmed that the contracts were signed following the completion of all required official approvals from the countries involved in transferring these advanced pharmaceutical industries to Iraq. The initiative falls within a strategic vision aimed at strengthening national pharmaceutical security and reducing reliance on imported medicines.
The authority explained that the project includes the establishment of an integrated pharmaceutical industrial city that will adopt the latest global technologies in biopharmaceutical production, including treatments for chronic and incurable diseases. The project places particular emphasis on knowledge and technology transfer, as well as the training of Iraqi personnel in accordance with international standards.
The statement noted that this initiative represents a qualitative leap in Iraq’s pharmaceutical industry, contributing to the development of the national healthcare system, the enhancement of scientific research and medical education, the creation of quality job opportunities, and support for the national economy.
The Health and Medical Education Authority of the Holy Shrine of Imam Hussain continues to implement major strategic projects aimed at localizing advanced pharmaceutical industries and transferring modern knowledge and technology to Iraq, in line with efforts to strengthen pharmaceutical security and advance healthcare and medical education nationwide.
If you want this tightened further into a shorter news report, headline-focused version, or official communiqué, I can refine it accordingly.



